purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation tmo earnings call period ending march image source motley fool thermo fisher scientific tmo q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning lady gentleman welcome thermo fisher scientific first quarter conference call name angela coordinating call today operator instruction would like introduce moderator call mr rafael tejada vice president investor relation mr tejada may begin callrafael tejada vice president investor relation good morning thank joining u call today marc casper chairman president chief executive officer stephen williamson senior vice president chief financial officer please note call webcast live archived investor section website thermofishercom heading news event presentation may copy press release first quarter earnings available investor section website heading financials begin let briefly cover safe harbor statement various remark may make company future expectation plan prospect constitute forwardlooking statement purpose safe harbor provision private security litigation reform act actual result may differ materially indicated forwardlooking statement result various important factor including discussed company recent annual report form k file sec available investor section website heading financials sec filing may elect update forwardlooking statement point future specifically disclaim obligation even estimate changetherefore rely forwardlooking statement representing view date subsequent today also call referring certain financial measure prepared accordance generally accepted accounting principle gaap reconciliation nongaap financial measure directly comparable gaap measure available press release first quarter earnings also investor section website heading financials turn call marc marc casper chairman president chief executive officer thank raf good morning everyone thanks joining u today first quarter call saw press release great start year delivered another quarter strong financial performance proud team ongoing focus enabling success customer demonstrating incredibly strong commercial execution operational discipline continued success result proven growth strategy ppi business system let first recap financials revenue quarter billion adjusted operating income billion expanded adjusted operating margin q delivered another quarter strong adjusted eps performance achieving increase year year per share performance first quarter allowing u raise guidance set u deliver differentiated performance turning performance endmarket first quarter underlying market condition played would expected team excellent execution enabled u deliver differentiated revenue performance ahead expectation let provide additional context starting pharma biotech declined low singledigits quarter sequential improvement performance q first quarter vaccine therapy revenue runoff resulted three point headwind customer segment also delivered strong growth clinical research business quick reminder academic government industrial applied year ago strong shipment analytical instrument worked backlog caused pandemicrelated supply chain disruption result academic government declined lowsingle digit quarter delivered strong growth electron microscopy business well research safety market channel industrial applied declined low singledigits quarter delivered strong growth electron microscopy business segment finally diagnostics healthcare q declined high singledigits reported growth endmarket impacted runoff covid testingrelated revenue quarter core revenue growth highlighted transplant diagnostics immunodiagnostics business well healthcare market channel wrapping endmarkets underlying market condition played expected start year recall assumption see modest pickup economic activity year progress quarter good see couple positive development endmarkets support view including continued improvement biotech funding environment stimulus program announced china turn update growth strategy reminder strategy consists three pillar highimpact innovation trusted partner status customer unparalleled commercial engine starting first pillar highimpact innovation excellent start year launching number new product across business firstquarter let first highlight number product analytical instrument demonstrate continued market leadership chromatography mass spectrometry business launched thermo scientific dionex inuvion ion chromatography system enables higher resolution faster timetoresults streamline workflow efficiently identify contaminant environmental testing chemical analysis business launched thermo scientific linspector edge inline metrology solution enhance battery safety performance production also launched thermo scientific truscan g handheld raman analyzer nextgeneration handheld instrument rapid identification chemical compound used drug production life science solution launched axiom pangenomix array highthroughput microarray use human genomic study across global population including disease risk detection research well population scale disease research program another strong quarter product launch one highlight highimpact innovation quarter named one fast company magazine innovative company great external recognition impact team driving customer moving second pillar strategy trusted partner status many year give unique opportunity connect customer senior executive team since beginning year many meeting customer turning u ever reinforce partnership well help navigate opportunity challenge face conversation happening across company level organization customer see team part culture always finding better way every day serf reinforce trusted partner status customer take lightly trust customer company continue partner closely enable innovation productivity first example clinical nextgeneration sequencing business quarter announced collaboration bayer develop nextgeneration sequencingbased companion diagnostic help identify patient may benefit bayer growing portfolio precision cancer therapy second example analytical instrument business partnering north carolina collaboratory support pfas research capacity state help identify implement solution address pfas contamination first network kind use several stateoftheart instrument including orbitrap astral research finally clinical research business share two example trusted partner status come life customer look solution unmet need expanded portfolio gmp lab service include qpcrbased biosafety testing capability detection bacteria contaminant medicine offering enables significantly faster result versus traditional testing method allowing quicker delivery medicine patient launched corevitas syndicated clinical registry generalized pustular psoriasis address unmet need realworld evidence related outcome patient rare disease recall corevitas became part company last year business performing well making difference customer patient great example trusted partner status let turn ppi business system enables outstanding execution quarter ppi engages empowers colleague find better way every day see strong profitability cash flow delivered first quarter looking forward team actively utilizing generative ai part ppi business system increase efficiency productivity well continually improve customer experience across company share couple example applying ai enabling u accelerate software development timeline analytical instrument life science solution business also leveraging combination large language model vast differentiated amount data disposal one benefit seeing ability enhance capability technical customer service team effectively serve customer generative ai another great example continually strengthen impact ppi business system let give update corporate social responsibility initiative missiondriven company help make world better place enabling important work customer also positive impact supporting community good steward planet focusing stem education advancing global health equity end first quarter announced collaboration south african medical research council together establish center excellence training program focused molecular biology life science facility provide specialized education support professional development scientist laboratory professional africa also pleased share thermo fisher achieved perfect score human right campaign foundation corporate equality index eighth year row let give update capital deployment continue successfully execute disciplined capital deployment strategy combination strategic returning capital shareholder quarter reached oneyear anniversary binding site acquisition protein diagnostics business financial performance tracking ahead deal model really strong growth recently chance visit headquarters protein diagnostics business saw great progress making given exciting new product positively impact patient care multiple myeloma turning planned acquisition olink working regulatory process transaction track close mid look forward welcoming new colleague company later year term return capital quarter repurchased billion share increased dividend reflect quarter proud team accomplished grateful contribution success nice recognition team track record thermo fisher included fortune magazine list admired company let turn guidance given stronger operational performance start year raising guidance expect revenue range billion billion expect adjusted eps range per share stephen take detail remark summarize key takeaway first quarter delivered another quarter strong financial result driven proven growth strategy ppi business system continue enable customer success continually reinforces trusted partner status strong result q position u deliver differentiated performance continue create value stakeholder build even brighter future company hand call cfo stephen williamson stephenstephen williamson senior vice president chief financial officer thanks marc good morning everyone take overview first quarter result total company provide color four business segment conclude providing updated guidance get detail financial performance let provide highlevel view first quarter played versus expectation time last earnings call q market condition would expected another quarter excellent execution enabled u deliver q financials meaningfully ahead would assumed prior guidance core organic revenue million ahead adjusted eps ahead give color strong profitability pullthrough revenue beat phasing spending within year lower fx headwind lower net interest expense continuing manage business really well great start year let provide additional detail performance beginning earnings per share quarter grew adjusted eps gaap eps quarter q last year top line q reported revenue lower year year component q reported revenue change included lower organic revenue slight contribution acquisition q core organic revenue decreased quarter pandemicrelated revenue approximately million including million vaccine therapy related revenue turning organic revenue performance geography q north america declined midsingledigits europe declined low singledigits asiapacific china declined low singledigits respect operational performance team used ppi business system execute really well quarter delivering billion adjusted operating income revenue basis point higher q last year total company adjusted gross margin quarter came basis point higher q last year quarter continued deliver strong productivity reflecting continued focus cost management well carryover benefit cost action put place last year enabled u offset impact lower volume appropriately funding investment advance industry leadership moving detail pl adjusted sga quarter revenue total rd expense million q reflecting ongoing investment highimpact innovation rd percent manufacturing revenue quarter looking result line q net interest expense million million lower q due increased cash balance adjusted tax rate quarter average diluted share million q approximately million lower year year driven share repurchase net option dilution turning free cash flow balance sheet strong start year cash flow generation q cash flow operation billion free cash flow q million investing million net capital expenditure continued return capital shareholder q increase dividend billion share buyback completed january ended quarter billion cash shortterm investment billion total debt leverage ratio end quarter time gross debttoadjusted ebitda time net debt basis concluding comment total company performance adjusted roic reflecting strong return investment generating across company provide color performance four business segment starting life science solution q reported revenue segment declined organic revenue lower prior year quarter driven moderation pandemicrelated revenue segment well lower level activity bioproduction business versus yearago quarter q adjusted operating income life science solution increased adjusted operating margin basis point versus prior year quarter q delivered exceptionally strong productivity partially offset unfavorable volume pullthrough team continues excellent job appropriately manage cost base deal unwind pandemic analytical instrument segment reported revenue declined organic growth lower prior year quarter continue deliver strong growth electron microscopy business reminder strong comparison segment quarter due high level instrument shipment q last year worked backlog segment q adjusted operating income decreased adjusted operating margin basis point lower year year quarter delivered strong productivity offset unfavorable volume mix strategic investment turning specialty diagnostics q reported revenue organic revenue flat versus prior year quarter q continued see strong underlying growth core led transplant diagnostics immunodiagnostics business well healthcare market channel q adjusted operating income specialty diagnostics increased adjusted operating margin basis point higher q quarter delivered favorable business mix good productivity partially offset strategic investment finally laboratory product biopharma service segment reported revenue organic growth decreased q versus prior year quarter driven runoff vaccine therapy revenue quarter delivered strong growth clinical research business q adjusted operating income declined adjusted operating margin basis point lower q quarter delivered strong productivity offset unfavorable volume mix strategic investment turning guidance marc outlined given strong start year raising fullyear guidance expect revenue range billion billion adjusted eps range midpoint reflects core revenue increase million continue assume core organic revenue growth range minus positive continue assume market decline low singledigits year growth strategy ppi business system execution enable u continue take share term adjusted eps increase guidance midpoint majority core revenue raise also assumed lower net interest expense versus prior guidance updated guidance range assumes adjusted operating income margin slightly improved prior guide continue use ppi business system enable excellent execution manage cost appropriately fund right longterm investment enable u advance industry leadership great start year increasing guidance outlook remain well positioned continue deliver differentiated performance thought would helpful remind key underlying assumption behind guide remain unchanged previous guidance assuming million testing revenue million million vaccine therapiesrelated revenue total represents yearoveryear headwind billion billion revenue assume fx roughly neutral year year revenue adjusted eps given recent fx rate change assuming beat saw q offset remainder year leading change year whole fx versus prior guide expect adjusted income tax rate assuming billion billion net capital expenditure free cash flow range billion billion term capital deployment assuming billion share buyback completed january expect return approximately million capital shareholder year dividend continue assume close olink acquisition midyear full year average diluted share count assumed approximately million share finally wanted touch quarterly phasing q expect revenue dollar step first quarter organic growth likely two point better q expect q adjusted eps similar q reflects revised view phasing spending within year mentioned earlier think view q pretty close currently baked consensus right conclude delivered commitment q great position deliver differentiated performance stakeholder turn callback rafrafael tejada vice president investor relation operator ready qa portion call question answer operatorthank mr tejada operator instruction first question doug schenkel wolfe research line opendoug schenkel wolfe research analyst good morning guy thank taking question simply put better start expected year marc share color one quarter progress two progression really momentum heading second quarter thing inform thinking outlook balance yearmarc casper chairman president chief executive officer thanks thought spirit continuous improvement ppi would frame key point qa session get question indulge second think key point one start long term serve awesome industry bright future right think drive bright future durable growth driven great science strong pipeline unmet medical need think first quarter zooming short term market condition line expectation really strong execution quarter resulted financial performance ahead expectation allowed u retire risk well raise fullyear outlook reminding investor assumed guidance going see modest stepup pickup economic activity year progress quarter really good see couple positive development endmarkets support view pickup year progress continued improvement biotech funding environment stimulus program announced china know define success deliver differentiated shortterm performance strong emphasis share gain strengthening competitive position long term q another quarter achieved doug think phasing quarter market really played exactly thought looked different part really aggregate piece really played way quarter unfolded would say see huge change pattern although march little bit better first couple month way easter laid kind make little bit hard know exactly felt like march good exit rate consistent modest stepup baked would say april first couple week kind playing welldoug schenkel wolfe research analyst ok super helpful thank highlevel thought well could maybe kind doubleclick area focus u lab product service stronger expected relative certainly model tell consensus particular obviously cro cdmo business focus u seeing fair say thing picking little bit better maybe better expected keeping mind early update cdmo peer relatively encouraging think maybe cro side would see impact kind keeping mind q best biopharma funding quarter five year make feel outlook next several quarter year aheadstephen williamson senior vice president chief financial officer yes doug tee kind view versus consensus personally going talk kind business dynamic guide segment term organic growth u came marc said market came expected aggregate thing segment executed well huge outperformance part beat kind pretty much across board companymarc casper chairman president chief executive officer yeah get dynamic one thing would call cro capability clinical research former ppd business really excellent execution first quarter drove really strong performance proud team accomplished think market dynamic definitely seeing pipeline activity picking certainly know take actually materialize revenue given cycle business encouraging given biotech funding environment see level pipeline work picking thank dougoperatorthank next question mike ryskin bank america line openmike ryskin bank america merrill lynch analyst great thanks taking question congrats quarter marc want pick something mentioned called continued improvement biotech funding environment earlier talked stimulus china two positive development saw endmarket q think also acknowledge still relatively early going false start endmarkets course guess question give confidence really turned corner data point looking year progress especially given position china business council think better funding stimulus show revenue thermomarc casper chairman president chief executive officer yeah mike think great question like way framed well nothing false start way think super clear word choice assumed original guidance modest pickup two data point called would consistent view changing view upwards market rather going drive slight pickup fact biotech funding improving china announced stimulus program think everybody probably positively surprised announced early year trying get economy growing fact support modest stepup set even stronger set market condition enter think kind phasing going market thing would note quarter positive actually played expected right including four endmarkets good mean normal incredible visibility predictability typically business returning helpful wellmike ryskin bank america merrill lynch analyst ok really helpful doug asked lab product service let focus analytical instrument called electron microscopy continue well really tough comp maybe could focus little bit chromatography mass spec seeing endmarket perspective lot concern pharma capex budget sort trending early comment say part portfolio thanksmarc casper chairman president chief executive officer yeah mike think analytical instrument really good quarter strong comparison called compared highteens growth last year important flag let start electron microscopy get chroma mass spec electron microscopy business performing great level continues strong order book really good job feel great think chromatography mass spectrometry well incredibly strong comparison getting really good uptake astral really milestone level shipment product first nine month owning know launching gone well business highend research portion done well u little bit le exposure kind routine application know flag one product launched really quite relevant know strong market leader ion chromatography hear lot pfas testing thing sort launched next generation instrumentation great given large fleet around world product great start feel good outlook different piece highlighted couple interesting launch chemical analysis smallest three business enabling battery production really trying change way qaqc done pharmaceutical manufacturing raw material inspected factory versus lab testing handheld raman analyzer really great innovation drive growth business really good performance start yearoperatorthank next question jack meehan nephron research line openjack meehan nephron research analyst good morning guy wanted keep digging pharma business first question clinical research called strong growth clarification inclusive covid headwind talked tone sound positive comment around seeing would greatmarc casper chairman president chief executive officer yes adjustment business grew think year think guidance assumption embedded guidance reminded investor largest role clinical research supporting pandemic response also parallel incredible growth business really excellent start excellent execution deliver strong growth quarter expect business moderate year relative last year momentum bodes extremely well midterm high singledigit growth business plus synergy team done great job becoming part company leveraging relationship getting really strong commercial momentum really nice start yearjack meehan nephron research analyst awesome pharma service side little bit competitive shakeup novos proposed acquisition catalent talk win rate patheon feel runway future tech transfersmarc casper chairman president chief executive officer yeah jack think pharma service business performed well think industry dynamic gone area market leader sterile fillfinish put medicine vaccine final dosage form effectively one pureplay competitor taken cdmo business effectively le area capacity constrained already bodes really well business market leader great reputation activity level high number dialogue customer high securing new business feel great job trusted partner enable customer success right customer think decade industry event make uncertain whether biosecure whether acquisition one supplier look industry leader say company create uncertainty great job thing ultimately allow u better support customer going forwardoperatorthank next question rachel vatnsdal jp morgan line openrachel vatnsdal jpmorgan chase company analyst good morning congratulation quarter wanted dig comment around china stimulus little bit one hand language around stimulus fairly broad tranche also appears two half time dollar amount stimulus package benefited last year walk u hearing customer regarding stimulus working proposal customer yet even seen order related stimulus come albeit probably bit early follow comment around timeline stimulus look happened last year stimulus actually announced september really see impact early given delay initial announcement actually seeing benefit view could potentially see benefit year could ultimately dynamicmarc casper chairman president chief executive officer rachel thanks question share enthusiasm government effort stimulate economy get thing going interesting time respect stephen williamson senior vice president chief financial officer back mike comment view start destart poststart think good thing china trying find way stimulate economy think one element look forward thing happening well term way china managing economy marc right go aheadmarc casper chairman president chief executive officer yeah think actually way thing play lot signaling far tell experience worked china many year multiyear program opposed last one shorter term basically government signaling least economy looking investment instrumentation equipment technological advance advanced research encouraging term shortterm program rather longer term yes already proposal front customer yes quite bit dialogue customer actually waiting practical detail work varies province ultimately knowledge order yet would expect quickly anyway lot activity way would think direct effect indirect effect would expect would see order really later year revenue late year directly associated stimulus may miss month one way would expect material shipment q around u would way would think experience indirect effect confidence booster right basically saying government going try get economy going help broadly help tomorrow help contextual standpoint business confidence think thing would say seeing china try get economy growing assuming lot china number year term major change excited set see benefit year kind direction travel view longerterm china good growth market usrachel vatnsdal jpmorgan chase company analyst perfect really appreciate detail wanted stick china followup obviously seen headline around biosecure act heard customer talking trying derisk supply chain go western manufacturer given headline perspective wanted see impacting customer conversation seen increase inbounds term patheon timing benefit obviously pretty capacityconstrained sector right know mentioned catalentnovo dynamic earlier well could even benefit near term competitive win relating biosecure function capacity constraint really alludes value chain vertical integration thermo benefit longer term thank youmarc casper chairman president chief executive officer way think biosecure kind put context level geopolitical tension exist around world including u china never exactly clear whether thing become enacted job help customer navigate shifting landscape think highest level actually relation falling country bit always challenge think could play play think making customer base largely western term biotech pharmaceutical activity largely think supply chain development work etc given network effectively u western europe set capability likely longterm beneficiary per se act rather fact customer thinking partner partner based think long term ok think material impact result short term thank racheloperatorthank next question dan brennan td cowen line opendan brennan td cowen analyst great thanks question marc stephen maybe china know already discussion point marc could give u sense low singledigit decline quarter kind compare expectation remind u assumed full year kind color share demand trend across business segment chinamarc casper chairman president chief executive officer yeah think china actually played expected team delivered expectation quarter know guidance guide geography business really aggregate actually first quarter played team expected executed well kind go subsegments china getting tiny portion revenue nothing really significant note term thing better worse seeing would expect would highlevel view looking forward returning china early early summer get firsthand perspective welldan brennan td cowen analyst got maybe bioprocessing know consumable portion business marc call revenue net obviously tremendous focus right could give color business performed quarter color provide like ongoing destock issue whether seen order start grow sequentially thanksmarc casper chairman president chief executive officer yeah dan thanks question bioproduction definitely factor got queue question say emphasis reducing becoming little bit predictable really q line expectation organic growth decline expected quarter due strong comparison year ago look order two quarter row really good sequential booking growth nice improvement booktobill look thing said externally quarter feel really good performance term executed working line thought would happen thanks danoperatorthank next question matt sykes goldman sachs line openmatt sykes goldman sachs analyst hi good morning thanks taking question maybe revisiting ai segment maybe compare contrast endmarkets seeing greatest strength sound like industrial applied remained strong would love hear kind go biopharma applied industrial academic government sort phasing growth course year endmarkets ai thank youmarc casper chairman president chief executive officer sure think business one thing matt really manage end segment effectively produce certain amount product ship specific customer quarter ship industrial customer exact product biopharma customer therefore kind skews thing caveat around look part business industrial applied continues strong momentum semiconductor material science application electron microscopy strong term played difficult comparison business based shipment year ago strong segment term academic government pharma biotech pretty much played expected nothing really jumped significant term trend patternsmatt sykes goldman sachs analyst got followup lp margin know acquired ppd talked potential longterm margin expansion business could maybe talk leverage got within lp understanding revenue improvement would help lot lever get margin within lp expand timemarc casper chairman president chief executive officer start maybe stephen add additional thought think margin obviously different business clinical research business formerly ppd incredibly strong operational execution right actually look utilization rate modification thing ultimately drive margin great job executing really well obviously benefiting synergy outlined achieved synergy target cost side gone well really great job executing trial really well bodes well margin expansion along volume think pharma service underlying strong obviously enough capacity coming online also runoff covid revenue lose volume see shortterm pressure margin say team operating actually team operating well margin expand year progress future well thought margin know stephen anything elsestephen williamson senior vice president chief financial officer think pharma service side capacity coming online switching cost ramping facility bringing colleague able operate facility fact come right driversmarc casper chairman president chief executive officer thanks mattrafael tejada vice president investor relation operator time one questionoperatorthank last question time today luke sergott barclays line openluke sergott barclays analyst great thanks question want dig back biosecure act followup rachel asking wanted know marc guy hearing customer multinationals operate saying regarding assumption china retaliating maybe excluding region know seems pretty unlikely probably going limited something radar conversation havingmarc casper chairman president chief executive officer yeah really speculate prudent whether thing even come pas come pas response job great job supporting customer globally comply global regulation actual regulation spirit regulation various country good job navigating would think lukeluke sergott barclays analyst yeah ok stephen life science margin strong life science solution understand destocking le issue much stepup quarter restocking kind walk double click driver consider kind jumpoff point around range rest year anything modeling perspectivestephen williamson senior vice president chief financial officer luke really good margin profile segment really addressing cost base business given lower volume pandemic unwind kind bioproduction aspect really fundamentally addressing cost business team done great job way think thatmarc casper chairman president chief executive officer thank luke thanks everyone question let wrap pleased deliver strong quarter incredibly well positioned deliver differentiated performance continue create value stakeholder build even brighter future company look forward updating second quarter result july discussing bright future well outlook upcoming investor day september always thank support thermo fisher scientific thanks everyoneoperatoroperator signoff duration minutescall participantsrafael tejada vice president investor relationsmarc casper chairman president chief executive officerstephen williamson senior vice president chief financial officerdoug schenkel wolfe research analystmike ryskin bank america merrill lynch analystjack meehan nephron research analystrachel vatnsdal jpmorgan chase company analystdan brennan td cowen analystmatt sykes goldman sachs analystluke sergott barclays analyst tmo analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends thermo fisher scientific motley fool disclosure policy